Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Min, Kyung-Jin | - |
dc.contributor.author | Kwon, Sang-Hoon | - |
dc.contributor.author | Kim, Kidong | - |
dc.contributor.author | Kim, Sunghoon | - |
dc.contributor.author | Kim, Hyun Jung | - |
dc.contributor.author | Seong, Seok Ju | - |
dc.contributor.author | Song, Yong Jung | - |
dc.contributor.author | Lee, Keun Ho | - |
dc.contributor.author | Lee, Shin-Wha | - |
dc.contributor.author | Lee, Jeong-Won | - |
dc.contributor.author | Chang, Suk-Joon | - |
dc.contributor.author | Ju, Woong | - |
dc.contributor.author | Kim, Young-Tak | - |
dc.contributor.author | Lee, Jae-Koran | - |
dc.date.accessioned | 2021-09-01T18:15:42Z | - |
dc.date.available | 2021-09-01T18:15:42Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-03 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/67204 | - |
dc.description.abstract | In 2016, 9-valent human papillomavirus (HPV) vaccine has been newly introduced in Korea, thus the need to develop recommendations for the vaccine has raised. Until we decide to develop a guideline, no further studies on the bi-valent or quadri-valent HPV vaccine have been announced. We searched and reviewed the literatures focused on the efficacy of 9-valent HPV vaccine, the ideal age of 3-dose schedule vaccination, the efficacy of 9-valent HPV vaccine in middle-aged women, the efficacy of the 2-dose schedule vaccination, the safety of 9-valent HPV vaccine, the possibility of additional 9-valent HPV vaccination, and cross-vaccination of 9-valent HPV vaccine. So, Korean Society of Gynecologic Oncology (KSGO) developed a guideline only for 9-valent HPV vaccine. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY | - |
dc.subject | HUMAN-PAPILLOMAVIRUS INFECTION | - |
dc.subject | INTRAEPITHELIAL NEOPLASIA | - |
dc.subject | IMMUNOGENICITY | - |
dc.subject | SAFETY | - |
dc.title | Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Min, Kyung-Jin | - |
dc.contributor.affiliatedAuthor | Lee, Jae-Koran | - |
dc.identifier.doi | 10.3802/jgo.2019.30.e31 | - |
dc.identifier.scopusid | 2-s2.0-85062188797 | - |
dc.identifier.wosid | 000459705400013 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, v.30, no.2 | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.citation.title | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.citation.volume | 30 | - |
dc.citation.number | 2 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002442665 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.subject.keywordPlus | HUMAN-PAPILLOMAVIRUS INFECTION | - |
dc.subject.keywordPlus | INTRAEPITHELIAL NEOPLASIA | - |
dc.subject.keywordPlus | IMMUNOGENICITY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Papillomavirus Vaccines | - |
dc.subject.keywordAuthor | Practice Guidelines | - |
dc.subject.keywordAuthor | Female | - |
dc.subject.keywordAuthor | Male | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.